Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
November 02, 2022 16:02 ET
|
Matinas BioPharma Holdings, Inc.
EnACT Phase 2 study of MAT2203 in cryptococcal meningitis met its primary endpoint with 95% two-week patient survival in the Cohort 4 all-oral regimen Phase 3 pivotal trial of MAT2203 for treatment...